Quarterly Report April-June 2004

QUARTERLY REPORT APRIL – JUNE 2004

· Predevelopment candidate was identified in the Wyeth
Pharmaceuticals collaboration yielding milestone revenues for Karo Bio.
Research terms extended with one year.
· Bristol-Myers Squibb decided to return lead compound rights to
Karo Bio. Karo Bio is now evaluating returned compound KB2115 as a
candidate drug for treatment of obesity.
· Net sales amounted to MSEK 14.0 (50.8).
· The loss for the period amounted to MSEK 24.2 (18.1).
· Cash flows from operating activities amounted to MSEK -18.0 (-
0.6).
· Cash and cash equivalents and short-term investments amounted
to MSEK 126.0 (273.6) at the end of the period.
· Loss per share for the period amounted to SEK 1.43 (1.28).

Huddinge, July 13, 2004

Björn O. Nilsson
President & CEO

For further information, please contact
Björn O. Nilsson, President & CEO tel. +46 8 608 60 20,
Bertil Jungmar, Chief Financial Officer, tel. +46 8 608 60 52.

Legal disclaimer
This financial report includes statements that are forward looking and
actual results may differ materially from those stated. In addition to
the factors discussed, among other factors that may affect results are
developments within research programs, including development in pre-
clinical and clinical trials, the impact of competing research programs,
the effect of economic conditions, the effectiveness of the Company’s
intellectual property rights and preclusions of potential third party’s
intellectual property rights, technological development, exchange rate
and interest rate fluctuations, and political risks.

This report has not been subject to review by the Company’s independent
auditor.

Karo Bio AB (publ.), Novum, SE-141 57 Huddinge, Sweden.
Telephone: +46 8 608 60 00.
Fax: +46 8 774 82 61
Corporate identity number: 556309-3359
Website: www.karobio.com

————————————————————
This information was brought to you by Waymaker https://www.waymaker.net
The following files are available for download:
https://www.waymaker.net/bitonline/2004/07/13/20040713BIT00020/wkr0001.pdf The full report